Margetuximab for the treatment of HER2-positive metastatic breast cancer

Paolo Tarantino, Stefania Morganti, Jacopo Uliano, Federica Giugliano, Edoardo Crimini, Giuseppe Curigliano

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: No specific standard treatment is currently recommended for HER2-positive advanced breast cancer (BC) patients progressing to dual HER2 blockade and to trastuzumab emtansine (TDM-1). However, several novel anti-HER2 agents are emerging and rapidly revolutionizing this setting. Among these, the FC-engineered monoclonal antibody margetuximab has recently demonstrated to slightly improve progression-free survival (PFS) compared with trastuzumab, when combined with chemotherapy for pretreated HER2-positive advanced BC. Areas covered: The present review article recapitulates the clinical development of margetuximab, critically discussing its implications in the current landscape of BC treatment algorithms. Expert opinion: The clinical role of Margetuximab can only be interpreted in view of the rapidly evolving treatment landscape for pretreated HER2-positive advanced BC. Indeed, the recently approved anti-HER2 agents tucatinib and trastuzumab deruxtecan currently represent appealing options for the post-TDM1 setting, while margetuximab may have a role after progression to the abovementioned agents, in case of a future approval. Regardless of its clinical uptake, it should be noted that the development of margetuximab has relevantly improved our biological understanding of HER2-positive BC, highlighting the implication of patient’s genotype in determining treatment outcomes, as well as the relevance of antibody-dependent cellular cytotoxicity (ADCC) in the context of HER2-blockade.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume21
Issue number2
DOIs
Publication statusPublished - 2021

Keywords

  • breast cancer
  • her2
  • Margetuximab
  • mgah22
  • sophia trial

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Margetuximab for the treatment of HER2-positive metastatic breast cancer'. Together they form a unique fingerprint.

Cite this